With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.

Press Releases

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

Scott Struthers, Ph.D., Founder & CEO of Crinetics, will present a company update on Wednesday, January 13th at 1:30 pm Pacific Time. A live audio webcast of Dr. Struthers’ presentation may be accessed on the Events section of the company’s website or directly on the J.P. Morgan virtual meeting platform.

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics management, including Dr. Scott Struthers and Dr. Alan Krasner, will participate in the upcoming Evercore ISI 3rd Annual HealthCONx Conference and the Piper Sandler 32nd Annual Healthcare Conference in December.

Corporate Presentation

Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.